Retreatment with lenalidomide is an effective option in heavily pretreated refractory multiple myeloma patients

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F18%3A00106916" target="_blank" >RIV/00216224:14110/18:00106916 - isvavai.cz</a>

Alternative codes found

RIV/65269705:_____/18:00069473

Result on the web

<a href="http://dx.doi.org/10.4149/neo_2018_170519N363" target="_blank" >http://dx.doi.org/10.4149/neo_2018_170519N363</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.4149/neo_2018_170519N363" target="_blank" >10.4149/neo_2018_170519N363</a>

Result language

angličtina

Original language name

Retreatment with lenalidomide is an effective option in heavily pretreated refractory multiple myeloma patients

Original language description

The combination of lenalidomide and dexamethasone is the current gold standard for treatment of relapsed multiple myeloma. This study analyzes the efficiency of repeated lenalidomide treatment in patients with relapsed and refractory multiple myeloma. A total of 41 patients were prospectively evaluated at the University Hospital Brno. Lenalidomide was administered at standard dosing and in combination with corticosteroids and/or chemotherapy. The maximum cumulative dose of lenalidomide was limited to 4,200 mg because of Czech health insurance rules. Before the second lenalidomide treatment, all patients were refractory to the last treatment; previously, 95% of patients had bortezomib treatment, 48% had autologous transplantation and the median number of prior therapy lines was three. A partial 14.2% or better response was achieved with the second lenalidomide treatment. The median progression-free survival was 4.8 months, and median overall survival was 11.9 months. Unfortunately, predicting risk factors in lenalidomide retreatment proved unsuccessful. Although our treatment results were significantly affected by limited Czech health care system coverage for lenalidomide, we established that its repeated treatment is an effective therapeutic alternative for heavily pretreated patients with relapsed and refractory multiple myeloma.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30204 - Oncology

Project

<a href="/en/project/NV15-29508A" target="_blank" >NV15-29508A: Circulating nucleic acids as markers of multiple myeloma progression</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2018

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Neoplasma

ISSN

0028-2685

e-ISSN

1338-4317

Volume of the periodical

65

Issue of the periodical within the volume

4

Country of publishing house

SK - SLOVAKIA

Number of pages

7

Pages from-to

585-591

UT code for WoS article

000440172400012

EID of the result in the Scopus database

2-s2.0-85051249874